IonGate Raises $1.4M to Expand US Business
IonGate Biosciences said this week that it has raised €1 million ($1.4 million) in a new round of private funding from Hessen Kapital I.
The Frankfurt, Germany-based firm said that it would use the funds to expand its business in the US and increase global commercialization of its SURFE2R technology. IonGate recently launched its SURFE2R Workstation 5000 for functional screening of transporters in higher-throughput pharmaceutical discovery and development (see CBA News, 8/1/08).
Earlier this year, IonGate raised €4.6 million in a third round of private financing with investors Heidelberg Innovation and Kreditanstalt für Wiederaufbau. The firm also established a New York-based subsidiary to help marketing efforts for the SURFE2R platform (see CBA News, 1/18/08).
BD Taps AnaSpec to Manufacture Fluorescent Dyes
AnaSpec announced this week that BD Biosciences has chosen it to manufacture and supply the BD H7, Calcein AM, and DiIC12(3) fluorescent dyes.
H7 is the abbreviation of HiLyte FluorTM 750 Bis-NHS ester, which carries two amine-reactive groups, succinimidyl esters, on each dye molecule for general labeling of protein amine groups.
BD APC-H7 is a tandem conjugate and an analog of APC-CyTM7 with the same spectral properties. It has decreased intensity, but it is engineered for greater stability and less spillover in the APC channel compared to APC-Cy7, the manufacturer said.
BD Calcein AM fluorescent dyes can be used to fluorescently pre- and post-label viable cells to perform kinetic and endpoint experiments, respectively. DiIC12(3) is a lipophilic neuronal tracer, which is commonly used for the labeling of neuronal projections as well as lipid bilayers in other cell types. DiIC12(3) exhibits low toxicity and minimal effects on cell viability, so it can be used to pre-label cells for a variety of applications.
BD DiIC12(3) fluorescent dye can be used to fluorescently label viable cells for assays, such as tumor cell invasion or endothelial cell migration. Cells labeled with DiIC12(3) can be used for several days in culture without adverse effects.
Invitrogen, ABI Combo to Have Four Core Divisions
As the acquisition of Applied Biosystems by Invitrogen draws closer, the firms announced this week that the newly merged company would operate under four core divisions: molecular biology systems, genetic systems, cell systems, and mass spectrometry systems.
They also announced the management team that will oversee these four divisions and other functions.
The molecular biology systems division will be led by Peter Dansky, who currently serves as leader of ABI’s molecular and cell biology functional analysis division. It will include the workflows of both firms related to molecular biology, such as gene expression, genotyping, gene regulation, and proteomics.
The genetic systems division will be led by Kip Miller, who currently serves as leader of Invitrogen’s Biodiscovery division. It will include ABI’s capillary electrophoresis and SOLiD sequencing systems, as well as Invitrogen’s third-generation sequencing development program.
The cell systems division will be led by Nicolas Barthelemy, who currently heads Invitrogen’s cell systems division. It will include Invitrogen’s current cell systems operations and ABI’s Poros and Tropix business lines.
The mass spectrometry division will be led by Laura Lauman, who currently leads ABI’s proteomics and small molecule division, and will house ABI’s mass spec business.
As previously announced, Invitrogen Chairman and CEO Greg Lucier will hold the same titles for the merged company, which will retain the Applied Biosystems name. ABI President and COO Mark Stevenson will retain those titles following the merger.
Invitrogen also said this week that it expects to complete within the next seven days a $2.65 billion bank facility to partially fund its roughly $6.7 billion acquisition of Applied Biosystems.